Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Reza Dana, MD
Study ID
NCT00681889
Phase
PHASE1
Status
Completed

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    10 Patients will receive treatment (Ranibizumab)

Study Details

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

Key Dates

First listed
May 21, 2008
Start date
Apr 30, 2008
Status verified
Oct 2012
Primary completion
Sep 30, 2009
Completion
Sep 30, 2010

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm
    10 Patients will receive treatment (Ranibizumab)

Primary Outcome Measure

Incidence and Severity of Ocular Adverse Event [ Time Frame: 16 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts Eye and Ear InfirmaryBostonMassachusetts02114-

Find similar trials in Boston, MA

By research site
Massachusetts Eye and Ear Infirmary· Boston, MA

Related Studies